

Exploring Your Next Opportunities in Austria: Life Science Industry

探索您的下一个投资机遇：奥地利的生命科学行业

Online, 16 December 2020

在线论坛，2020年12月16日



Background of the Forum

论坛背景介绍：

Life Sciences and Medical Technology are among the most important technological and economic areas of the 21st century. Austria offers networks of well-established pharmaceutical companies, innovative biotechnology firms, leading research institutes and important centres of expertise, providing the ideal backdrop for a life science location.

More than 820 companies in the fields of biotechnology, pharmaceuticals and medical engineering generate 5.8 percent of the country's gross domestic product (GDP) and employ a workforce of approximately 52,000 people. The focal points of the research being conducted include oncology, neurology, vaccines and immunology as well as precision medicine and e-health.

Vienna is the hub of the Austrian biotechnology and pharmaceutical industry. Every second biotech company is located in Vienna, including the Campus Vienna Biocenter, one of the leading biomedical research centers in Central and Eastern Europe. All top 20 global players in the sector operate a presence in Vienna. Many have a sales unit and a clinical research unit in the city, for example Novartis, Pfizer and Takeda. Besides, Vienna is home to a growing number of innovative start-ups.

We invite you to join the webinar to learn more about Life Science in Austria and the governmental support for starting up business in Austria.

生命科学与制药是 21 世纪最重要的技术和经济领域之一。在奥地利，有着成熟的制药公司、创新的生物技术企业、领先的研究机构以及重要的专家中心组成的网络，为生命科学企业选址提供了理想的环境。

来自生物技术、制药和医学工程领域的 820 多家公司为奥地利创造了 5.8% 的 GDP，提供约 52,000 的工作岗位。研究的重点领域包括肿瘤学、神经学、疫苗和免疫学以及精密医疗、电子健康。

维也纳是奥地利的生物技术与制药行业中心，全国约半数的生物技术企业选址于此，包括中东欧顶尖的生物医药研究中心——维也纳生物中心。在维也纳您会发现这一行业全球排名 20 强的所有企业。包括诺华、辉瑞和武田在内的许多企业在维也纳设有销售部门和临床研究部门。此外，越来越多的创新型初创公司选择了落户维也纳。

我们诚挚邀请您参加本次网络研讨会，了解有关奥地利生命科学的更多信息，以及政府对外商投资企业在奥地利开展业务的相关扶持。

Program:
会议日程:

- 08:30-08:35
CET
- Welcome Speech**
欢迎辞
Mr. Matthias Adelwöhrer , ABA-Invest in Austria, Director Asia
Matthias Adelwöhrer 先生, 奥地利国家投资促进局, 亚洲总监
- 08:35-08:45
CET
- Overview of Economic Relationship and Cooperation between Austria and China**
中奥经济关系与合作概况
Ms. Elisabeth Mindlberger, Vice Consul (Commercial Affairs), Austrian Consulate General Shanghai
闵艾林女士, 奥地利共和国驻上海总领事馆, 商务副领事
- 08:45-09:00
CET
- Start Your Business in Austria: Opportunities under the New Conditions**
奥地利: 新形势下的投资机遇
Ms. Shanshan Wu, ABA-Invest in Austria, Chief Advisor China
乌姗姗女士, 奥地利国家投资促进局, 中国首席代表
- 09:00-09:10
CET
- Vienna: Where You Can Enjoy Success**
Ms. Jennifer Zhang, Regional Manager Asia, Vienna Business Agency
张晓军女士, 维也纳商务局, 亚洲地区经理
- 09:10-09:25
CET
- Life Science City Vienna**
维也纳的生命科学产业
Mr. Phillip Hainzl, Managing Director, LISA Vienna
Phillip Hainzl 先生, 维也纳生命科学产业集群, 总经理
- 09:25-09:35
CET
- The Life Science Ecosystem in Austria from an Investors Perspective**
从投资人角度看奥地利的生命科学生态系统
Dr. Katherine Cohen, Venture Partner, Panacea Venture
程琦博士, 瑞伏医疗创投基金, 投资合伙人
- 09:35-09:45
CET
- Getting Your Life Science Company Started in Austria: First Hand Experience**
经验分享: 在奥地利创建生命科学企业
Dr. Achim Plum, Managing Director, Ares Genetics GmbH
Achim Plum 博士, Ares Genetics 有限责任公司, 董事总经理
- 09:45-09:55
CET
- Q&A Session**
问答互动环节

CVs of Partial Speakers:

部分演讲嘉宾介绍

Mr. Philipp Hainzl has been representing the Vienna Business Agency in a management capacity at the Vienna life sciences platform LISAVienna since September 2020. As head of the Business Agency's life sciences team, he also helps shape strategic decisions on the future development of this sector in Vienna. Philipp Hainzl is responsible for the Vienna Business Agency's Startup Labs at the Vienna BioCenter and is committed to providing additional laboratory space for companies in Vienna.

His career path so far has taken him from academic research via biotech start-ups and all the way to "big pharma". In addition to a broad knowledge base gained from his degree in genetic engineering & biotechnology, he brings valuable experience in biotech and pharmaceutical management, lean management and process optimization and in sales and customer support to LISAVienna.

Philipp Hainzl 自2020年9月以来一直在维也纳生命科学平台LISA Vienna 担任管理部门的维也纳商业代表。作为商业机构生命科学团队的负责人，他还帮助制定了维也纳这一行业未来发展的战略决策。Philipp Hainzl负责维也纳生物中心的维也纳商业机构的启动实验室，并致力于为维也纳的公司提供更多的实验室空间。

他迄今为止的职业道路是生物技术初创公司进行学术研究，一直到“大型制药公司”。除了获得遗传工程和生物技术学位的广泛知识基础之外，他还为LISA Vienna 带来了在生物技术和药物管理，精益管理和流程优化以及销售和客户支持方面的宝贵经验。

Dr. Katherine Cohen joined Panacea Venture in 2018 as a Venture Partner for healthcare and biotech investment. She has over 25 years of experience in the biotech and pharmaceutical industry and is a qualified European Patent Attorney. Before joining Panacea Venture, Dr. Cohen served as CEO at Hookipa Biotech AG (now Hookipa Pharma Inc.), where she was responsible for founding the company together with a Nobel Prize winner group (Prof. Zinkernagel from University of Zurich). Dr. Cohen led the Series A and B venture financing rounds, and under her leadership Hookipa grew from a research start-up to a clinical stage company. Prior to Hookipa, Dr. Cohen was Senior Vice President for Corporate and Business Development at Intercell AG (now Valneva SE) where she was part of the leadership responsible for the growth of the company from a start-up to a successful public and commercial stage enterprise. Prior to her biotech entrepreneurial career, Dr. Cohen worked in the area of R&D at Sandoz/VIRCC. Dr. Cohen earned her Ph.D in Biology at the City University of New York. Dr. Cohen is an honorary professor at the University of Applied Sciences in Austria and a guest professor for Business Law LLM at Vienna University Law School jointly established with Stanford University.

程琦博士于2018年加入瑞伏医疗创投基金，担任专注生物医药领域投资的投资合伙人。程博士在生物技术和制药行业拥有超过25年的业务和领导经验。自2011年到2016，她曾担任Hookipa Biotech AG的创始首席执行官，成功融资A&B轮，带领公司从诺贝尔实验室走到临床及工业化。该公司是一家利用病毒载体平台开发下一代癌症免疫治疗及传染病疫苗的生物技术公司，在美国纳斯达克上市。此前，程博士是Intercell AG（今Valneva SE）业务发展高级副总裁，在1999年至2011年的12年里，她领导并负责将该公司从一家创业公司逐步转变为一家欧洲主要的疫苗公司，在2007-2009年，公司市值达到了17亿欧元；程博士对Intercell的主要价值成长事件做出了重要贡献，领导进行了包括VC融资，IPO，以及与大型制药厂商的战略联盟和并购。程博士具有欧洲专利律师资格，她拥有美国纽约市立大学的生物学博士学位和武汉大学学士学位。程博士还是奥地利应用科技大学的名誉教授、斯坦福大学和维也纳大学联合国际商业法律硕士课程的受邀客座教授。

Ms. Jennifer Zhang was born in Shanghai, China. She has been lived in Vienna since 1990. In the last 30 years, Jennifer Zhang has worked for different sizes of Austrian Companies in different fields, such as Trade, Petro chemistry Industry, Telecommunications and Intelligent Transport Systems.

Jennifer studied Elementary education in Shanghai; she got her Master Degree in Vienna for Business Entrepreneurship in 2006.

Since June 2006, Jennifer Zhang has been working for the City Government of Vienna – Vienna Business Agency – Department of International Business. Her focus is to promote Vienna as Business location and give a wide range of services for supporting international investors setting up business in Vienna.

Especially she is in charge of Great China (incl. Taiwan, Hong Kong) and other Asian countries, e.g. South Korea, Japan, Singapore, etc.

张晓军女士，出生于中国上海。1990年到奥地利维也纳定居。在近30年的奥地利生活期间，分别在奥地利不同领域和不同规模的公司，比如贸易，石油化工工业，电信，智能化工业公司工作。

张女士毕业于上海第一师范学院。2002至2006年在维也纳经济专科学校进修并取得经济硕士学位。2006年六月至今在维也纳市政府直属的维也纳商务局任职。主要负责大中国地区，亚洲其他地区的招商及维也纳作为投资所在地的推介工作。

Dr. Achim Plum, Managing Director of Ares Genetics GmbH, has 20 years of management experience in the diagnostics industry with a focus on innovative molecular diagnostics, biomarker development, and personalized medicine. He started Ares Genetics together with Dr. Andreas Posch in 2017 as a subsidiary of the German Curetis Group (now OpGen Group) that he joined as Managing Director and CCO/CBO in 2015. Prior to Curetis, he held a Senior Management position at Siemens Healthcare where he was responsible for Diagnostic and Bio-Science Technology & Innovation. Before Siemens, Dr. Plum worked for eight years at the cancer molecular diagnostics company Epigenomics, lastly as SVP Business & Strategy. Noteworthy, Epigenomics developed and commercializes the first FDA-cleared liquid biopsy test for colorectal cancer screening. Dr. Plum studied Genetics, Cell Biology and Biochemistry in Bonn, Germany, and Norwich UK. He obtained his Ph.D. in Molecular Genetics from the University of Bonn in 1999 and was awarded numerous prizes and scholarships during his academic career.

Ares Genetics GmbH 董事总经理 **Achim Plum 博士**在诊断行业拥有 20 年的管理经验，专注于创新分子诊断，生物标志物开发和个性化医学。他于 2017 年与 **Andreas Posch 博士**一起创立了成为德国 Curetis 集团（现为 OpGen 集团）子公司的 Ares Genetics，于 2015 年加入该集团公司担任董事总经理兼 CCO / CBO。在加入 Curetis 之前，他曾在西门子担任高级管理职位。他负责诊断和生物科学技术与创新的医疗保健。在加入西门子之前，Plum 博士在癌症分子诊断公司 Epigenomics 工作了 8 年，最后担任业务与战略高级副总裁。值得注意的是，Epigenomics 开发并商业化了第一个 FDA 批准的用于结肠直肠癌筛查的液体活检方法。

Plum 博士在德国波恩和英国诺里奇学习遗传学，细胞生物学和生物化学。他于 1999 年在波恩大学获得分子遗传学博士学位，并在他的学术生涯中获得过无数奖项和奖学金。

Type of the Event/活动形式:

Online Forum, the detailed login information will be provided after your registration.

在线活动，我们将在您报名后，发送给在线会议系统登入地址

Time/时间:

Dec. 16 2020 08:30– 09:55 CET

2020年12月16日中欧时间 08:30-09:55，北京时间15:30-16:55

Language: Chinese and English simultaneous interpretation

语言：中文及英语同声翻译

Registration/活动登记

Please register until **8th December 2020** by using the attached registration form.

请于**2020年12月8日**前使用随附的报名表格进行活动登记。

Contact Information/联系方式

For further information, please contact

如需进一步信息请联系：

Shanshan Wu 乌珊珊

shanshan.wu@advantageaustria.org

+86 21 62897123-13